STOCKS TELEGRAPH

Tag: Codexis

  • New Contract Propels Codexis (CDXS) Stock Upward, Signaling Market Optimism

    New Contract Propels Codexis (CDXS) Stock Upward, Signaling Market Optimism

    Shares of Codexis, Inc. (NASDAQ: CDXS) experienced a sharp rise, climbing 22.16% to $3.12 per share following the announcement of a significant revenue-generating contract. This surge reflects growing investor confidence in the company’s innovative enzymatic synthesis technology and its expanding role in the biopharmaceutical industry.

    First Revenue-Generating Contract for ECO Synthesis

    The first revenue-generating contract for the synthesis of small interfering RNA (siRNA) material has been formally obtained by Codexis, a major supplier of enzymatic solutions for scalable therapeutics manufacturing. This agreement will be carried out at CDXS’ recently opened ECO Synthesis Innovation Lab, enhancing the proprietary ECO Synthesis platform’s industrial suitability.

    Codexis’ double-stranded RNA (dsRNA) ligation technology has been successful in the past, and this contract builds on that accomplishment. The business has made significant progress in commercializing its platform by effectively creating a suite of enzymes that can power the ECO Synthesis process on an industrial scale. At future scientific conferences, CDXS will submit data showing how their enzymatic method may equal or even exceed the efficiency of conventional chemical synthesis.

    Scaling Up: Partnerships and Industrial Viability

    Codexis has recently validated the technical feasibility of its ECO Synthesis approach through collaborations with multiple industry partners. Codexis was the first to demonstrate four different pathways for producing an authorized siRNA treatment when it presented groundbreaking results at the TIDES Europe annual meeting in November 2024.

    Potential partners have shown a great deal of interest in these innovative developments, which has resulted in many successful feasibility studies. Among them, Codexis completed studies with Bachem, a leading manufacturer of siRNA therapeutics, and another major innovator in the field.

    Future Growth and Industry Impact

    With the completion of its ECO Synthesis Innovation Lab, the company is now well-positioned to convert ongoing collaborations into formal revenue-generating contracts. The lab facilitates the delivery of GLP-grade siRNA material to its partners and offers analytical and process development services.

    Codexis has effectively proven the end-to-end enzymatic synthesis of inclisiran by utilizing its exclusive Enzyme Catalyzed Oligonucleotide (ECO) Synthesis platform. CDXS wants to change the siRNA therapeutics manufacturing environment as it expands its creative enzymatic solutions.

  • Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

    Rapid Rise: Codexis (CDXS) Stocks Surge After Key Licensing Deal

    As of the last check this current trading session, Codexis, Inc. (NASDAQ: CDXS) was observed to have surged by 30.47%, reaching $4.18. This upward trend in Codexis stock value is propelled by an announcement of a significant licensing agreement.

    Codexis (CDXS) has formalized an exclusive, worldwide licensing deal with Roche, pertaining to the Company’s freshly engineered double-stranded DNA (dsDNA) ligase designed for next-generation sequencing (NGS) library preparation, alongside the EvoT4 DNA ligase. According to the terms outlined in the agreement, Codexis stands to gain upfront payments as well as technical milestone reimbursements. Notably, this agreement supplants the prior exclusive license concerning the EvoT4 DNA ligase.

    This transaction epitomizes the ongoing dedication of Codexis to concentrate on the pivotal sectors of its enterprise, where it can wield the most significant influence in the market. Since the articulation of its prioritized strategy last July, Codexis has successfully executed numerous agreements aimed at monetizing its non-core assets in collaboration with leading entities in the market.

    The renewal of collaboration with Roche on the innovative dsDNA ligase is a source of great anticipation. As a pioneer in NGS technologies, Roche consistently introduces crucial kits to the market, ensuring the requisite sensitivity and specificity for the forthcoming wave of pioneering NGS applications. Leveraging Roche’s technical expertise and expansive commercial footprint, Codexis now possesses the means to fully exploit the potential of its dsDNA ligase.

    Engineered through Codexis’ proprietary CodeEvolver technology, this recently developed dsDNA ligase enhances the ligation efficiency of DNA fragments and adapters during NGS library preparation, devoid of any bias. This advancement is particularly advantageous for NGS workflows demanding the utmost sensitivity, even under constraints of limited starting material.

    Compared to the wild-type enzyme, the newly engineered dsDNA ligase demonstrates superior ligation efficiency within shorter reaction durations, yielding higher library outputs and complexity while exhibiting minimal substrate sequence bias.

    Additionally, the Company is scheduled to participate in the TD Cowen 44th Annual Health Care Conference, slated for March 4-6, 2024, in Boston, Massachusetts. CDXS Management is set to engage in a fireside chat on Monday, March 4, 2024, at 2:50 pm ET.

  • Momentum Continues For Codexis (CDXS) Stock After-Hours

    Momentum Continues For Codexis (CDXS) Stock After-Hours

    Codexis, Inc. (NASDAQ: CDXS) shares, having experienced a notable upswing in the standard trading session on Wednesday, sustained their momentum in the extended session. The after-market trading witnessed Codexis stock registering a robust 12.92% increase, reaching $2.36. This ascent followed a 4.50% upturn in CDXS stock during the regular session, concluding at $2.09. The surge in stock value can be attributed to strategic maneuvers employed by the company.

    Codexis (CDXS) announced to formalize an agreement with Aldevron, a prominent global player in the tailored development and production of plasmid DNA, RNA, and proteins for the biotech sector. Per the terms of the agreement, Aldevron secures a global exclusive license for Codexis’ Codex HiCap RNA Polymerase.

    In return, Aldevron gains worldwide manufacturing and commercialization rights for the Codex HiCap RNA Polymerase, with CDXS receiving compensation for imminent technical milestones, as well as commercial and sales-based royalties. Collaboratively, CDXS and Aldevron are committed to ensuring a seamless transition for customers during the transitional phase.

    Teaming up with Aldevron, a leading manufacturer of mRNA, enhances CDXS’s market reach, providing a pathway to a GMP-grade version of its Codex HiCap RNA Polymerase. This development facilitates the efficient production of mRNA-based therapeutics, potentially impacting a substantial patient population.

    The successful execution of this partnership underscores Codexis’ adeptness in extracting value from its transformative enzyme portfolio by strategically placing them in the hands of suitable collaborators.

    In a separate announcement yesterday, CDXS revealed the accomplishment of gram-scale synthesis using its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis technology. This pivotal technical achievement signifies the preparative-scale production of an oligonucleotide, comprising modified nucleotide building blocks commonly utilized in RNA therapeutics, under conditions akin to industrial processes.

    The successful attainment of this milestone empowers Codexis engineers to commence a thorough evaluation of the purity profile for small interference RNA (siRNA) developed through ECO Synthesis technology. Anticipated early access customer testing is scheduled to commence in 2024, paving the way for a comprehensive commercial launch in 2026.

  • Codexis, Inc. (CDXS) and Casdin Capital team up to Launch SynBio Innovation Accelerator

    Codexis, Inc. (CDXS) and Casdin Capital team up to Launch SynBio Innovation Accelerator

    Codexis, Inc. (NASDAQ: CDXS), a major biotechnology company that builds and supplies differentiated enzyme items for high-value markets, has officially launched the SynBio Innovation Accelerator in partnership with relevant life science investor Casdin Capital. The accelerator’s aim is to finance and foster early-stage companies in the far-reaching and revelatory field of synthetic and industrial biotechnology with disruptive technology platforms or unique product development capabilities. Casdin Capital plans to invest upwards of $50 million in companies linked to the industry and the SynBio Innovation Accelerator over the next several years.

    John Nicols, President, and CEO of Codexis said that as the Genomic Revolution transformed our ability to read and translate the blueprint of life, and in the process enabled a second and equally powerful SynBio revolution, we are at a tipping point for Synthetic Biology. The company currently has a phenomenal ability to write and engineer transformative biological products, not just to read DNA. ace has shown us that delivering distinct products to the market takes more than just capital.

    Eli Casdin, Casdin Capital’s Managing Partner, said that this is not the first collaborative effort of this kind we have entered into, having built a similar initiative with BioLife Solutions in the bio-production space. Technology there has been successfully triggered by the accelerator model and we are convinced that it will have an even larger effect in the space of synthetic biology and stimulate the growth of this evolving field of technology.

    The SynBio Innovation Accelerator’s first investment is in a company for computational protein design, Arzeda, where Codexis and Casdin are making a $1.75 million investment together. In addition to this investment in capital, Codexis and Arzeda expect to work together on synergy and mutual benefit areas. The initial focus will be on continuing the work of both companies to broaden the scope and advantage of machine learning and artificial intelligence as functional products or tools in the development of new, impactful enzymes. Arzeda is an emerging protein engineering player, with a core focus on computational approaches to the design of novel functionality of enzymes. The Company will leverage the existing proprietary informatics tools of Codexis and its highly effective workflows for screening and optimization.